donny-strosberg

A. Donny Strosberg is Professor of Infectology at The Scripps Research Institute in Florida where he manages a program on Hepatitis C. His current work focuses on developing novel small molecule therapeutics based on inhibition of protein-protein interactions (see recent papers: Kota et al., 2009a, 2009b). His group also develops a new infectious HCV genotype 1b culture system which is resistant to interferon.

Prof. Strosberg was trained as a Dr. Sci at the Free University of Brussels and did a post-doctoral fellowship at Massachusetts General Hospital in Boston. After serving at the Harvard Medical School as an Instructor and later as a Visiting Professor, he became Professor of Biochemistry and Immunology first in Brussels, then in Paris. With his teams he published over 360 peer-reviewed original scientific articles, several books and dozens of book chapters. He authored over twenty issued patents of which several were licensed to pharmaceutical companies.

Prof. Strosberg is a co-founder of several biotechnology companies including Chemunex, co-founded with the University of Paris; Incyte, Praecis, co-founded with M.I.T.; BioRelix co-founded with Yale University; and most recently Protix Therapeutics, co-founded with The Scripps Research Institute. From 1998 to 2004 Prof. Strosberg was the Chairman and CEO of Hybrigenics, a company, which he co-founded with the Pasteur Institute from 1998 to 2004.

Press Release

March 9, 2009